EHA 2024: Updates in the Treatment of CLL    - Episode 15

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

, , , ,

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024
    EP. 2: Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
    EP. 3: Frontline BTKi Selection
    EP. 4: Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib
    EP. 5: Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy
    EP. 6: Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
    EP. 7: EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches
    EP. 8: Navigating Treatment Approaches for R/R CLL
    EP. 9: How Experts View MAIC Data That was Presented at EHA 2024
    EP. 10: BTKi Intolerance in Real-world Practice & Management Strategy
    EP. 11: Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
    EP. 12: Approach to Hypertension Management With BTKi Treatment
    EP. 13: Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
    EP. 14: Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
    Now Viewing
    EP. 15: Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
    EP. 16: TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
    EP. 17: EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
    EP. 18: Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673
    EP. 19: Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL
    EP. 20: Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
    EP. 21: Clinical Pearls and Impacts to Practice from EHA 2024

    Video content above is prompted by the following questions:

    • Briefly comment on the recent FDA accelerated approval granted to pirtobrutinib based on findings from BRUIN.
      • How are you currently using pirtobrutinib in the clinical practice setting and how do you sequence it with other available therapies?
      • Is there a potential role for pirtobrutinib in earlier lines of therapy?
    x